ArticleBMC cancer2025
FAM111B knockdown attenuates tumorigenesis of ovarian cancer via the downregulation of MYC.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pan-cancer analysis identifies FAM111B as a biomarker for immune suppression microenvironment in low-grade gliomas.Translational cancer research · 2026Article
- Linking FAM111B to metabolic-immune remodeling in breast ductal carcinoma.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOvarian cancer, a prevalent malignancy with the highest fatality rate among gynecological cancers, continues to face challenges in the development of effectively targeted therapeutic approaches. While the FAM111B gene has been implicated in various cancer types, its specific role in ovarian cancer remains poorly understood.
methodsThe ES2 and A2780 ovarian cell lines were exploited to explore the cellular proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in FAM111B knockdown experiments. We constructed a mouse tumor model to investigate the impact of FAM111B silencing in vivo; employed tissue microarray to explore the prognostic value of different FAM111B expression levels; and applied western-blot assay, MYC-overexpression rescue experiments, protein transcriptomics, and bioinformatics analysis to examine the downstream molecular mechanisms underlying FAM111B actions.
resultsOur in vitro experiments indicated that the inhibition of FAM111B resulted in reduced cellular proliferation, migration, invasion, and EMT in ovarian cancer cell lines and in the suppression of tumor growth in a mouse xenograft model. Immunohistochemical analyses conducted on tissue-microarray samples obtained from patients with serous ovarian cancer indicated that elevated levels of FAM111B expression were associated with unfavorable prognostic outcomes. The silencing of FAM111B mechanistically constrained MYC expression, with subsequent MYC overexpression reversing the phenotypic suppression caused by FAM111B silencing. Additionally, protein transcriptomic analysis implicated FAM111B in genetic-information processing via the MYC pathway, underscoring FAM111B's central role in ovarian cancer tumorigenesis.
conclusionsThese findings suggest that FAM111B may serve as a novel biomarker and potential therapeutic target in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.